Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents

Jaeki Min, Kexiao Guo, Praveen K. Suryadevara, Fangyi Zhu, Gloria Holbrook, Yizhe Chen, Clementine Feau, Brandon M. Young, Andrew Lemoff, Michele C. Connelly, Michael B. Kastan, R. Kiplin Guy

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We previously reported a novel inhibitor of the ataxia-telangiectasia mutated (ATM) kinase, which is a target for novel radiosensitizing drugs. While our initial lead, compound 4, was relatively potent and nontoxic, it exhibited poor stability to oxidative metabolism and relatively poor selectivity against other kinases. The current study focused on balancing potency and selectivity with metabolic stability through structural modification to the metabolized site on the quinazoline core. We performed extensive structure-activity and structure-property relationship studies on this quinazoline ATM kinase inhibitor in order to identify structural variants with enhanced selectivity and metabolic stability. We show that, while the C-7-methoxy group is essential for potency, replacing the C-6-methoxy group considerably improves metabolic stability without affecting potency. Promising analogues 20, 27g, and 27n were selected based on in vitro pharmacology and evaluated in murine pharmacokinetic and tolerability studies. Compound 27g possessed significantly improve pharmacokinetics relative to that of 4. Compound 27g was also significantly more selective against other kinases than 4. Therefore, 27g is a good candidate for further development as a potential radiosensitizer.

Original languageEnglish (US)
Pages (from-to)559-577
Number of pages19
JournalJournal of Medicinal Chemistry
Volume59
Issue number2
DOIs
StatePublished - Jan 28 2016

Fingerprint

Radiation-Sensitizing Agents
Ataxia Telangiectasia
Phosphotransferases
Quinazolines
Pharmacokinetics
Structure-Activity Relationship
Pharmacology

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Medicine(all)

Cite this

Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. / Min, Jaeki; Guo, Kexiao; Suryadevara, Praveen K.; Zhu, Fangyi; Holbrook, Gloria; Chen, Yizhe; Feau, Clementine; Young, Brandon M.; Lemoff, Andrew; Connelly, Michele C.; Kastan, Michael B.; Guy, R. Kiplin.

In: Journal of Medicinal Chemistry, Vol. 59, No. 2, 28.01.2016, p. 559-577.

Research output: Contribution to journalArticle

Min, J, Guo, K, Suryadevara, PK, Zhu, F, Holbrook, G, Chen, Y, Feau, C, Young, BM, Lemoff, A, Connelly, MC, Kastan, MB & Guy, RK 2016, 'Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents', Journal of Medicinal Chemistry, vol. 59, no. 2, pp. 559-577. https://doi.org/10.1021/acs.jmedchem.5b01092
Min, Jaeki ; Guo, Kexiao ; Suryadevara, Praveen K. ; Zhu, Fangyi ; Holbrook, Gloria ; Chen, Yizhe ; Feau, Clementine ; Young, Brandon M. ; Lemoff, Andrew ; Connelly, Michele C. ; Kastan, Michael B. ; Guy, R. Kiplin. / Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 2. pp. 559-577.
@article{24daf1416232407fa49212dd25abf82a,
title = "Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents",
abstract = "We previously reported a novel inhibitor of the ataxia-telangiectasia mutated (ATM) kinase, which is a target for novel radiosensitizing drugs. While our initial lead, compound 4, was relatively potent and nontoxic, it exhibited poor stability to oxidative metabolism and relatively poor selectivity against other kinases. The current study focused on balancing potency and selectivity with metabolic stability through structural modification to the metabolized site on the quinazoline core. We performed extensive structure-activity and structure-property relationship studies on this quinazoline ATM kinase inhibitor in order to identify structural variants with enhanced selectivity and metabolic stability. We show that, while the C-7-methoxy group is essential for potency, replacing the C-6-methoxy group considerably improves metabolic stability without affecting potency. Promising analogues 20, 27g, and 27n were selected based on in vitro pharmacology and evaluated in murine pharmacokinetic and tolerability studies. Compound 27g possessed significantly improve pharmacokinetics relative to that of 4. Compound 27g was also significantly more selective against other kinases than 4. Therefore, 27g is a good candidate for further development as a potential radiosensitizer.",
author = "Jaeki Min and Kexiao Guo and Suryadevara, {Praveen K.} and Fangyi Zhu and Gloria Holbrook and Yizhe Chen and Clementine Feau and Young, {Brandon M.} and Andrew Lemoff and Connelly, {Michele C.} and Kastan, {Michael B.} and Guy, {R. Kiplin}",
year = "2016",
month = "1",
day = "28",
doi = "10.1021/acs.jmedchem.5b01092",
language = "English (US)",
volume = "59",
pages = "559--577",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents

AU - Min, Jaeki

AU - Guo, Kexiao

AU - Suryadevara, Praveen K.

AU - Zhu, Fangyi

AU - Holbrook, Gloria

AU - Chen, Yizhe

AU - Feau, Clementine

AU - Young, Brandon M.

AU - Lemoff, Andrew

AU - Connelly, Michele C.

AU - Kastan, Michael B.

AU - Guy, R. Kiplin

PY - 2016/1/28

Y1 - 2016/1/28

N2 - We previously reported a novel inhibitor of the ataxia-telangiectasia mutated (ATM) kinase, which is a target for novel radiosensitizing drugs. While our initial lead, compound 4, was relatively potent and nontoxic, it exhibited poor stability to oxidative metabolism and relatively poor selectivity against other kinases. The current study focused on balancing potency and selectivity with metabolic stability through structural modification to the metabolized site on the quinazoline core. We performed extensive structure-activity and structure-property relationship studies on this quinazoline ATM kinase inhibitor in order to identify structural variants with enhanced selectivity and metabolic stability. We show that, while the C-7-methoxy group is essential for potency, replacing the C-6-methoxy group considerably improves metabolic stability without affecting potency. Promising analogues 20, 27g, and 27n were selected based on in vitro pharmacology and evaluated in murine pharmacokinetic and tolerability studies. Compound 27g possessed significantly improve pharmacokinetics relative to that of 4. Compound 27g was also significantly more selective against other kinases than 4. Therefore, 27g is a good candidate for further development as a potential radiosensitizer.

AB - We previously reported a novel inhibitor of the ataxia-telangiectasia mutated (ATM) kinase, which is a target for novel radiosensitizing drugs. While our initial lead, compound 4, was relatively potent and nontoxic, it exhibited poor stability to oxidative metabolism and relatively poor selectivity against other kinases. The current study focused on balancing potency and selectivity with metabolic stability through structural modification to the metabolized site on the quinazoline core. We performed extensive structure-activity and structure-property relationship studies on this quinazoline ATM kinase inhibitor in order to identify structural variants with enhanced selectivity and metabolic stability. We show that, while the C-7-methoxy group is essential for potency, replacing the C-6-methoxy group considerably improves metabolic stability without affecting potency. Promising analogues 20, 27g, and 27n were selected based on in vitro pharmacology and evaluated in murine pharmacokinetic and tolerability studies. Compound 27g possessed significantly improve pharmacokinetics relative to that of 4. Compound 27g was also significantly more selective against other kinases than 4. Therefore, 27g is a good candidate for further development as a potential radiosensitizer.

UR - http://www.scopus.com/inward/record.url?scp=84970929760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970929760&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.5b01092

DO - 10.1021/acs.jmedchem.5b01092

M3 - Article

C2 - 26632965

AN - SCOPUS:84970929760

VL - 59

SP - 559

EP - 577

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 2

ER -